Clinical trials: Early Parkinson's Disease
Parkinson Disease
Ophthalmologic Safety Study of Pramipexole Immediate Release (IR) Versus Ropinirole in Early Parkinson's Disease (PD) Patients
To determine if there is any difference in the presence of retinal deterioration in PD patients treated with pramipexole IR versus ropinirole as monitored by comprehensive ophthalmologic assessments from baseline to the end of…
- Trial name
- NCT00144300
- Testing
- Mirapex, Requip
- Where
- 21 sites in United States
- Volunteers
- 246 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine
The objective of this trial is to assess the effects of transdermal rotigotine on the control of early morning motor function and sleep disorders compared to placebo in subjects with idiopathic Parkinsons´s disease.
- Trial name
- RECOVER (NCT00474058)
- Testing
- Rotigotine
- Where
- 47 sites in United States, Australia and 10 more
- Volunteers
- 287 people
- Sponsor
- UCB Pharma
Parkinson's Disease
A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients
The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.
- Trial name
- NCT02337725
- Testing
- TVP-1012
- Where
- 55 sites in Japan
- Volunteers
- 244 people
- Sponsor
- Takeda
Early Parkinson Disease
PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706
This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving…
- Trial name
- NCT03655236
- Testing
- K0706
- Where
- 78 sites in United States, Hungary and 4 more
- Volunteers
- 513 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Parkinson Disease
Study of the Neuro-protective Effect of Granulocyte-colony Stimulating Factor on Early Stage Parkinson's Disease
The purpose of this study is to evaluate the effectiveness of neuroprotection from granulocyte colony-stimulating factor on Parkinson disease
- Trial name
- NCT01227681
- Testing
- G-CSF
- Where
- Taiwan
- Volunteers
- 4 people
- Sponsor
- Buddhist Tzu Chi General Hospital
Parkinson Disease
Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)
This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple HB-adMSCs vs Placebo for the treatment of Parkinson's disease.
- Trial name
- PD (NCT04928287)
- Testing
- HB-adMSCs
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Hope Biosciences Research Foundation
Parkinson Disease
A Placebo- and Active-Controlled Study of Preladenant in Early Parkinson's Disease (PD) (P05664)
This is a one year, 2-part study to determine the efficacy and safety of preladenant, an adenosine type 2a (A2a) receptor antagonist.
- Trial name
- PARADYSE (NCT01155479)
- Testing
- Preladenant 2 mg tablet, Preladenant 5 mg tablet, Preladenant 10 mg tablet
- Volunteers
- 1,022 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants
The purpose of this study is to evaluate the long-term safety of TVP-1012 (1 mg/day) in Japanese participants with early Parkinson's disease.
- Trial name
- NCT02337751
- Testing
- TVP-1012 1mg
- Where
- 56 sites in Japan
- Volunteers
- 198 people
- Sponsor
- Takeda
Parkinson's Disease
Deep Brain Stimulation (DBS) for Early Stage Parkinson's Disease (PD)
Bilateral subthalamic nucleus deep brain stimulation (B-STN DBS) is one of the most effective surgical treatments for PD patients suffering from levodopa-induced motor complications.
- Trial name
- NCT00282152
- Testing
- B-STN DBS, Optimal drug therapy
- Volunteers
- 37 people
- Sponsor
- Vanderbilt University Medical Center
Parkinson Disease
Safety of Urate Elevation in Parkinson's Disease
The purpose of this study is to determine the safety and tolerability of inosine and its ability to raise urate levels in blood and cerebral spinal fluid in individuals with early Parkinson disease.
- Trial name
- SURE-PD (NCT00833690)
- Testing
- inosine
- Where
- 16 sites in United States
- Volunteers
- 75 people
- Sponsor
- The Parkinson Study Group
Early Stage Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease
- Trial name
- NCT00599196
- Testing
- Rotigotine
- Where
- 63 sites in Australia, Austria and 18 more
- Volunteers
- 381 people
- Sponsor
- UCB Pharma
Parkinson Disease
Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)
This is a double blind, placebo-controlled clinical trial of 15 months duration designed to examine early Mirapex (pramipexole) treatment vs. delayed Mirapex (pramipexole) treatment in patients with new onset Parkinsons disease
- Trial name
- NCT00321854
- Testing
- pramipexole
- Where
- 99 sites in United States, Austria and 8 more
- Volunteers
- 535 people
- Sponsor
- Boehringer Ingelheim
Early-stage Parkinson's Disease
A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
The purpose of the study is to assess the safety and tolerability of UCB0599 and to demonstrate the superiority of UCB0599 over placebo with regard to clinical symptoms of disease progression over 12 and 18 months in participants…
- Trial name
- ORCHESTRA (NCT04658186)
- Testing
- UCB0599
- Where
- 115 sites in United States, Canada and 7 more
- Volunteers
- 496 people
- Sponsor
- UCB Biopharma SRL
Parkinson Disease
A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
This study is a Phase III, multicentre, randomized, initial double-blind study with subsequent open label phases. The study will havea screening phase (4 weeks), a dose increase effect verification phase (12 weeks), a down…
- Trial name
- NCT01929317
- Testing
- Ropinirole CR 2mg tablet, Ropinirole CR 8mg tablet
- Where
- 17 sites in Japan
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Early-Stage Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- SP512OL (NCT00594165)
- Testing
- Rotigotine
- Where
- 42 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- UCB Pharma
Parkinson Disease
Flexible-Dose Trial in Early Parkinson's Disease (PD)
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
- Trial name
- TEMPO-2 (NCT04223193)
- Testing
- Tavapadon
- Where
- 53 sites in United States, Australia and 11 more
- Volunteers
- 304 people
- Sponsor
- AbbVie
Parkinson Disease
Efficacy and Safety of TJ0113 Capsule in Patients With Parkinson's Disease
A randomized, double-blind, placebo parallel-controlled Phase II clinical trial to evaluate the efficacy and safety of TJ0113 capsule in patients with early-stage Parkinson's disease
- Trial name
- NCT06596005
- Testing
- TJ0113 200mg, TJ0113 400mg
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Parkinson Disease
Fixed-Dose Trial in Early Parkinson's Disease (PD)
The purpose of this study is to evaluate the clinical efficacy, safety and pharmacokinetics (PK) of 2 fixed doses of tavapadon and placebo in participants with early PD.
- Trial name
- TEMPO-1 (NCT04201093)
- Testing
- Tavapadon
- Where
- 77 sites in United States, Australia and 10 more
- Volunteers
- 529 people
- Sponsor
- AbbVie
Parkinson Disease
A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients
Primary objective: to assess the efficacy of pramipexole given two times daily compared to placebo. Secondary objectives: to assess the effects of pramipexole on mood, cognition, fatigue, impulse control, daytime sleepiness and…
- Trial name
- NCT00402233
- Testing
- Pramipexole
- Where
- 39 sites in United States
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
Parkinson Disease
Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression
The purpose of this project is to assess the change in dopamine transporter density in Parkinson's disease subjects during a sixty month period including a nine month treatment trial of levodopa.
- Trial name
- ELLDOPA (NCT00134784)
- Testing
- [123I]B-CIT SPECT imaging
- Volunteers
- 142 people
- Sponsor
- Institute for Neurodegenerative Disorders